EU OKs Bristol-Myers, AstraZeneca diabetes drug

by The Associated Press

(AP)—Drugmakers Bristol-Myers Squibb Co. and AstraZeneca PLC say their experimental diabetes pill has gotten its first major approval, in the European Union.

Forxiga (for-SEE'-gah), a once-a-day pill for adult Type 2 diabetes patients, is the first drug approved in a new class called SGLT2 inhibitors.

Known chemically as dapagliflozin (da-pah-GLEH'-flo-zihn), Forxiga works independently of insulin to remove excess blood sugar from the body differently than other Type 2 .

It can be taken alone or with insulin or other medicines that lower blood sugar.

Last January, the U.S. said it wouldn't approve the drug without more data. Bristol-Myers says the two drugmakers now plan to provide additional data from ongoing patient studies and reapply for approval in mid-2013.

0 shares

Related Stories

FDA: Bristol-Myers diabetes drug appears safe

date Mar 30, 2009

(AP) -- A potential blockbuster diabetes medication from Bristol-Myers Squibb appears free from heart-related side effects that have plagued similar treatments, federal health officials said Monday.

Recommended for you

GlaxoSmithKline opts to hold on to HIV business

date 4 hours ago

British-based drugmaker GlaxoSmithKline opted Wednesday to keep its stake in its stand-alone HIV business as it set out its strategy following a big deal with Switzerland's Novartis.

FDA petitioned to stop sales of essure implant

date 20 hours ago

(HealthDay)—Bayer's contraceptive implant Essure can cause serious complications and should be taken off the market, says a citizen's petition filed with the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.